AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
Log in

NASDAQ:EXELExelixis Stock Price, Forecast & News

$23.14
-0.34 (-1.45 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$22.94
Now: $23.14
$23.79
50-Day Range
$21.62
MA: $23.71
$25.76
52-Week Range
$13.67
Now: $23.14
$27.80
Volume1.43 million shs
Average Volume2.45 million shs
Market Capitalization$7.10 billion
P/E Ratio24.88
Dividend YieldN/A
Beta1.54
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Read More
Exelixis logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.10 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.78 million
Cash Flow$1.07 per share
Book Value$5.55 per share

Profitability

Net Income$321.01 million

Miscellaneous

Employees484
Market Cap$7.10 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

How has Exelixis' stock been impacted by COVID-19 (Coronavirus)?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXEL stock has increased by 33.1% and is now trading at $23.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Exelixis?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Exelixis.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Exelixis.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported $0.15 EPS for the quarter, topping the Zacks' consensus estimate of $0.13 by $0.02. The biotechnology company had revenue of $226.90 million for the quarter, compared to analysts' expectations of $216.64 million. Exelixis had a return on equity of 18.01% and a net margin of 30.01%. The firm's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.27 EPS. View Exelixis' earnings history.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850-900 million, compared to the consensus revenue estimate of $886.93 million.

What price target have analysts set for EXEL?

12 equities research analysts have issued 1-year price targets for Exelixis' shares. Their forecasts range from $21.00 to $40.00. On average, they anticipate Exelixis' share price to reach $28.92 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price. View analysts' price targets for Exelixis.

Has Exelixis been receiving favorable news coverage?

Media coverage about EXEL stock has been trending negative on Monday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Exelixis earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Exelixis.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 16,210,000 shares, an increase of 8.9% from the June 15th total of 14,880,000 shares. Based on an average daily trading volume, of 3,610,000 shares, the days-to-cover ratio is presently 4.5 days. Approximately 5.5% of the company's shares are short sold. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Who are Exelixis' key executives?

Exelixis' management team includes the following people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $23.06.

How big of a company is Exelixis?

Exelixis has a market capitalization of $7.07 billion and generates $967.78 million in revenue each year. The biotechnology company earns $321.01 million in net income (profit) each year or $1.02 on an earnings per share basis. Exelixis employs 484 workers across the globe.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.